Skip to main content

Table 7 Wilcoxon sign-rank test was used to test the difference between pre-PP1M and Post-PP1M. Comparison of Direct Costs, Indirect Costs and Total Costs Before and After Transition to PP1M

From: A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China

 

Direct costs

Indirect costs

Total costs

pre-PP1M (¥)

17,457±17,414

15,967±10,128

33,095±21,984

Post-PP1M (¥)

23,030±8648

10,279±11,878

33,309±15,254

Difference

31.92

-35.62%

0.64%

P

< 0.01

< 0.01

0.25